Skip to main content

Table 1 Survival analysis for 50 GBM patients treated with STUPP protocol.

From: DNA methylation in glioblastoma: impact on gene expression and clinical outcome

Variable

Univariate Cox Regression

Log Rank Test

Multivariate Cox Regression

 

HR

95% CI

p -value

ß cut-off

p -value

HR

95% CI

p -value

Age (≥ 50 yr vs. < 50 yr)

1.8

0.9 - 3.9

0.1

-

-

-

-

-

Sex (male vs. female)

1.5

0.8 - 2.8

0.3

-

-

-

-

-

KPS (≥ 80 vs. < 80)

1.2

0.6 - 2.3

0.6

-

-

-

-

-

TBX3

113

15.1 - 851.9

4.0E-06

0.45

1.0E-08

0.05

0.01 - 0.2

3.0E-05 (*)

FSD1

18

2.9 - 112

0.002

0.70

3.0E-07

0.2

0.09 - 0.6

0.002 (*)

FNDC3B

0.08

0.01- 0.4

0.002

0.55

7.0E-05

3.1

1.4 - 6.9

0.005

DGKI

77

9.5 - 616.5

4.0E-05

0.45

3.0E-06

0.3

0.1 - 0.7

0.008

FLJ25422

0.05

0.007 - 0.3

0.002

0.70

4.0E-04

2.9

1.2 - 7.2

0.02

SEPP1

0.008

0.003 - 0.2

0.004

0.10

2.0E-04

2.3

1.1 - 4.7

0.02

SOX10 #1

10

1.6 - 67.2

0.01

0.70

1.0E-04

0.4

0.2 - 0.9

0.03

CCND1

31

4.3 - 216

6.0E-04

0.75

2.0E-04

2.3

0.9 - 5.5

0.1

SOX10 #2

12

1.9 - 74.8

0.008

0.80

4.0E-04

0.5

0.2 - 1.2

0.1

ZNFN1A3

0.11

0.02 - 63.8

0.02

0.35

9.0E-04

1.8

0.8 - 4.2

0.2

MGMT

0,18

0.04 - 0.8

0.02

0.10

9.0E-06

-

-

-

  1. Log rank tests were performed between methylated and non-methylated patients. The multivariate analysis includes the methylation status of the tested CpG site and MGMT. MGMT methylation status was always significantly associated with OS (p-value < 0.05) and (*) indicates which CpG site had a lower p-value than the one observed for MGMT in the multivariate model. (yr = year; HR = Hazard Ratio; CI: Confidence Interval).